News Related to Acute Myeloid Leukemia with NPM1 Mutation

Related coverage linked through entity extraction aliases.

Kura Oncology's Ziftomenib Hits 96% CRc in Frontline AML, FIT-001 Data at 2026 Summit

Jul 20, 2026

Kura Oncology's ziftomenib shows 96% complete response in frontline AML and $5.8M in early commercial sales; updated FIT-001 trial data for kidney cancer to be presented at 2026 summit; analysts see significant upside with an average target of $32.45.

Ziftomenib-Chemotherapy Combo Shows 94% Survival in NPM1-Mutant AML

Jun 12, 2026

Updated KOMET-007 trial data show ziftomenib plus chemotherapy achieves 94% twelve-month overall survival in newly diagnosed NPM1-mutant AML. The oral menin inhibitor, approved by the FDA in November 2025 for relapsed/refractory disease, is being evaluated in a Japanese Phase II trial and a global Phase 3 study.